PMID- 16951271
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20131121
IS  - 0091-7370 (Print)
IS  - 0091-7370 (Linking)
VI  - 36
IP  - 3
DP  - 2006 Summer
TI  - Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and 
      clinical study.
PG  - 299-306
AB  - The plasma concentrations of natriuretic peptides, BNP and NTproBNP, have been 
      shown to be markers for the diagnosis of congestive heart failure (CHF). In this 
      study, plasma BNP and NTproBNP concentrations were evaluated and stratified 
      according to renal function, body mass index (BMI), and New York Heart 
      Association (NYHA) classification. Comparison studies between the 2 natriuretic 
      peptide markers were performed. Assays for BNP were performed with a Triage 
      reagent pack (Biosite, Inc) on an Access 2 immunoanalyzer (Beckman-Coulter); 
      NTproBNP assays were performed with a Roche reagent pack on an Elecsys 20.10 
      immunoanalyzer (Roche Diagnostics). Plasma samples were collected from 
      consecutive patients hospitalized for cardiac disorders at our institution. 
      Nonparametric tests were used for statistical analyses. The results show that 
      alterations of renal function had less impact on BNP (p = 0.9) than on NTproBNP 
      concentrations (p <0.0001). BNP and NTproBNP levels were lower in obese patients 
      with CHF (515 +/- 61 ng/L and 1652 +/- 124 ng/L, respectively) than in lean 
      patients (900 +/- 85 ng/L and 6686 +/- 749 ng/L). Although NTproBNP levels 
      averaged about 10 times higher than BNP levels, there was significant correlation 
      between these 2 markers (Deming regression r2 = 0.40, IC: 0.95). In conclusion, 
      plasma BNP and NTproBNP assays are both useful for the diagnosis of CHF and left 
      ventricular dysfunction. However, renal function and obesity must be taken into 
      account for clinical interpretation. These assays have good analytical 
      performance and the choice between them depends on local preference.
FAU - Bionda, Clara
AU  - Bionda C
AD  - Laboratoire de Biochimie et de Biologie Moleculaire, Hopital Cardio-Vasculaire et 
      Pneumologique L Pradel, Lyon, 28 Avenue Doyen Lepine, 69 677 Lyon, France. 
      clara.bionda@chu-lyon.fr
FAU - Bergerot, Cyril
AU  - Bergerot C
FAU - Ardail, Dominique
AU  - Ardail D
FAU - Rodriguez-Lafrasse, Claire
AU  - Rodriguez-Lafrasse C
FAU - Rousson, Robert
AU  - Rousson R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Creatinine/blood
MH  - Female
MH  - Heart Failure/blood/*diagnosis
MH  - Humans
MH  - Immunoassay/instrumentation/*methods
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Obesity/physiopathology
MH  - Peptide Fragments/*blood
MH  - Renal Insufficiency/*blood
MH  - Statistics, Nonparametric
EDAT- 2006/09/05 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - 36/3/299 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2006 Summer;36(3):299-306.